Published in final edited form as:

J Org Chem. 2009 March 20; 74(6): 2403–2412. doi:10.1021/jo802704h.

Side-chain to backbone interactions dictate the conformational preferences of a cyclopentane arginine analogue

Guillem Revilla-López¹, Juan Torras², Ana I. Jiménez³, Carlos Cativiela³, Ruth Nussinov^{4,5}, and Carlos Alemán^{1,*}

¹ *Departament d'Enginyeria Química, E. T. S. d'Enginyeria Industrial de Barcelona, Universitat Politècnica de Catalunya, Diagonal 647, Barcelona E-08028, Spain*

² *Departament d'Enginyeria Química, EUETII, Universitat Politècnica de Catalunya, Pça Rei 15, Igualada 08700, Spain*

³ *Departamento de Química Orgánica, Instituto de Ciencia de Materiales de Aragón, Universidad de Zaragoza – CSIC, 50009 Zaragoza, Spain*

⁴ *Basic Research Program, SAIC-Frederick, Inc. Center for Cancer Research Nanobiology Program, NCI, Frederick, MD 21702, USA*

⁵ *Department of Human Genetics Sackler, Medical School, Tel Aviv University, Tel Aviv 69978, Israel*

Abstract

The intrinsic conformational preferences of the non-proteinogenic amino acids constructed by incorporating the arginine side chain in the β position of 1-aminocyclopentane-1-carboxylic acid (either in a *cis* or a *trans* orientation relative to the amino group) have been investigated using computational methods. These compounds may be considered as constrained analogues of arginine (denoted as *c*₅Arg) in which the orientation of the side chain is fixed by the cyclopentane moiety. Specifically, the *N*-acetyl-*N'*-methanamide derivatives of *cis* and *trans*-*c*₅Arg have been examined in the gas phase and in solution using B3LYP/6-311+G(d,p) calculations and Molecular Dynamics simulations. Results indicate that the conformational space available to these compounds is highly restricted, their conformational preferences being dictated by the ability of the guanidinium group in the side chain to establish hydrogen-bond interactions with the backbone. A comparison with the behavior previously described for the analogous phenylalanine derivatives is presented.

Introduction

Among non-proteinogenic amino acids the conformational propensities of which can be exploited in the design of peptides analogues with well-defined backbone conformations are 1-aminocycloalkane-1-carboxylic acids¹ (known in the abbreviated form as Ac_{*n*}C, with *n* referring to the ring size). Within this series, the cyclopropane (Ac₃C),^{1,2} cyclobutane (Ac₄C),^{1,2c,3} cyclopentane (Ac₅C)^{1,2a,3b,4} and cyclohexane (Ac₆C)^{1,3b,5} members have been deeply investigated and shown to exhibit a restricted conformational space characterized by a high propensity to adopt $\phi\psi$ backbone angles typical of the ₁₀- α -helix (with some distortion in the case of Ac₃C).

*Correspondence to: E-mail: carlos.aleman@upc.edu.

Supporting Information

Coordinates and energy of the minimum energy conformations characterized for Ac-*t*-L-*c*₅Arg-NHMe and Ac-*c*-L-*c*₅Arg-NHMe. This material is available free of charge via the Internet at <http://pubs.acs.org>.

When considering a bioactive peptide, amino acids of the $Ac_n c$ family have proven appropriate replacements for proteinogenic residues bearing aliphatic or aromatic side chains.⁶ However, the $Ac_n c$ series may not be convenient to replace a proteinogenic amino acid containing a functionalized side chain which is directly involved in the peptide-receptor recognition process and is therefore essential for bioactivity. One may yet consider a new family of non-coded amino acids generated by attaching the functionalized side chain of a natural residue to the cycloalkane moiety in $Ac_n c$. This allows the combination of the necessary functionality with the particular conformational properties of the $Ac_n c$ residues (Figure 1). Moreover, this may enable the specific orientation of the side chain functionality by selecting the appropriate cycloalkane size and stereochemistry.

Specifically, we have been working on the synthesis⁷ and structural study⁸ –both theoretical and experimentally– of the amino acids obtained by incorporating a phenyl substituent at one of the β carbons of $Ac_n c$ ($n = 3-6$). The compounds thus obtained can be considered as phenylalanine (Phe) analogues and we denote them as $c_n Phe$, where n indicates the size of the cycle, as in $Ac_n c$. Since the phenylalanine side chain in $c_n Phe$ is included in a cyclic structure, the $C^\alpha-C^\beta$ bond can not rotate freely and, as a consequence, the orientation of the aromatic group is dictated by the size (n value) and stereochemistry of the cycloalkane ring. It should be noted that the additional phenyl substituent may exhibit a *cis* or a *trans* relative disposition with respect to the amino function. Accordingly, the different $c_n Phe$ stereoisomers can be regarded as a series of phenylalanine analogues with distinct well-defined side-chain orientations. Indeed, the different spatial arrangement attained by the aromatic substituent has proven useful in several applications related to the stabilization of particular peptide backbone conformations.^{8,9}

Within a project aimed at imparting protection against proteolytic cleavage to a bioactive peptide with simultaneous stabilization of a folded conformation, we became interested in the replacement of an arginine residue (Arg) by a non-natural analogue. In particular, we have focused our attention on the arginine analogue bearing an $Ac_5 c$ skeleton, that is, $c_5 Arg$ according to the nomenclature described above (Figure 1). As it can be seen, in $c_5 Arg$ the α carbon is separated from the guanidinium group by two carbon atoms, while this segment involves three carbon atoms in Arg. Therefore, from a rigorous point of view $c_5 Arg$ is a substituted $Ac_5 c$ -like derivative of nor-Arginine, where nor refers to a reduction of one carbon atom with respect to the side chain of conventional Arg. For an L configuration at the α carbon, the guanidylated side chain of arginine may exhibit a *trans* or a *cis* disposition relative to the amino moiety, respectively giving rise to *trans*- and *cis*- $c_5 Arg$ (Figure 2). It should be considered that the charged side chain of $c_5 Arg$ may interact with the backbone not only sterically but also electronically, and this may have a strong impact on the structural preferences of the peptide chain. In order to evaluate the behavior of the L enantiomer of both *trans*- and *cis*- $c_5 Arg$, we report a conformational study of the corresponding *N*-acetyl-*N'*-methanamide derivatives, hereafter denoted as *Ac-t-L-c₅Arg-NHMe* and *Ac-c-L-c₅Arg-NHMe*, respectively (Figure 2). Density Functional Theory (DFT) calculations at the B3LYP/6-311+G(d,p) level have been used to locate and characterize the minimum energy conformations. The influence of the solvent polarity on the conformational preferences has been examined using a Self Consistent Reaction Field (SCRF) method and molecular dynamics (MD) simulations with explicit solvent molecules.

Methods

The conformational properties of *Ac-t-L-c₅Arg-NHMe* and *Ac-c-L-c₅Arg-NHMe* have been investigated using the Gaussian-03 computer program.¹⁰ The structural search was performed considering that the compounds under study retain the restrictions imposed by the cyclopentane ring on the backbone in $Ac_5 c$.^{4a} Accordingly, the five minimum energy conformations

characterized for Ac-Ac₅c-NHMe in ref. ^{4a} were used to generate the starting structures for Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe. Although for Ac-Ac₅c-NHMe such five minima were two-fold degenerate due to the symmetry of the molecule, *i.e.* $\{\phi, \psi, \chi^i\} = \{-\phi, -\psi, -\chi^i\}$, the chiral nature of the two c₅Arg derivatives under study requires explicit consideration of both $\{\phi, \psi, \chi^i\}$ and $\{-\phi, -\psi, -\chi^i\}$ possibilities. The arrangement of the side group is defined by the flexible dihedral angles ξ_1 and ξ_2 , which are expected to exhibit three different minima: *trans* (180°), *gauche*⁺ (60°) and *gauche*⁻ (-60°). Consequently, 5 (minima of Ac-Ac₅c-NHMe) × 2 (chiral nature of c₅Arg) × 3 (minima of ξ_1) × 3 (minima of ξ_2) = 90 minima can be anticipated for the potential energy hypersurface (PEH) $E = E(\phi, \psi, \chi^i, \xi_1, \xi_2)$ of each c₅Arg-containing derivative. All these structures were used as starting points for subsequent full geometry optimizations.

All geometry optimizations were performed using the B3LYP functional^{11,12} combined with the 6-311+G(d,p) basis set.¹³ Frequency analyses were carried out to verify the nature of the minimum state of all the stationary points obtained and to calculate the zero-point vibrational energies (ZPVE) and both thermal and entropic corrections. These statistical terms were then used to compute the conformational Gibbs free energies in the gas phase at 298 K (ΔG_{gp}).

To obtain an estimation of the solvation effects on the relative stability of the different minima, single point calculations were conducted on the optimized structures using a SCRF model. Specifically, the Polarizable Continuum Model (PCM) developed by Tomasi and co-workers¹⁴ was used to describe water and chloroform as solvents. The PCM model represents the polarization of the liquid by a charge density appearing on the surface of the cavity created in the solvent. This cavity is built using a molecular shape algorithm. PCM calculations were performed in the framework of the B3LYP/6-311+G(d,p) level using the standard protocol and considering the dielectric constants of water ($\epsilon = 78.4$) and chloroform ($\epsilon = 4.9$) to obtain the free energies of solvation (ΔG_{solv}) of the minimum energy conformations. Within this context, it should be emphasized that previous studies indicated that solute geometry relaxations in solution and single point calculations on the optimized geometries in the gas phase give almost identical ΔG_{solv} values.¹⁵ The conformational free energies in solution (ΔG^{conf}) at the B3LYP/6-311+G(d,p) level were estimated using the classical thermodynamics scheme: $\Delta G^{conf} = \Delta G_{gp} + \Delta G_{solv}$.

MD simulations in water solution were performed using the NAMD program.¹⁶ The simulated peptides Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe were placed in the center of a cubic simulation box ($a = 31.1 \text{ \AA}$) filled with 338 explicit water molecules, which were represented using the TIP3 model,¹⁷ and a negatively charged chloride atom as counterion. Atom pair distance cutoffs were applied at 14 Å to compute van der Waals interactions. The electrostatic interactions were computed using the nontruncated electrostatic potential by means of Ewald Summations. The real space term was determined by the van der Waals cutoff (14 Å), while the reciprocal term was estimated by interpolation of the effective charge into a charges mesh with a grid thickness of 5 points per volume unit, *i.e.* the Particle-Mesh Ewald (PME) method.¹⁸ Bond lengths were constrained using the SHAKE algorithm¹⁹ and the numerical integration step was 2 fs.

Before the MD run series was started, 5×10^3 steps of energy minimization were performed to relax conformational and structural tensions. Different consecutive rounds of short MD runs were performed to equilibrate the density, temperature, and pressure: 0.50 ns of NVT-MD at 298 K (thermal relaxation) followed by 0.25 ns of isobaric relaxation (NPT-MD). Both temperature and pressure were controlled by the weak coupling method, the Berendsen thermostat²⁰ using a time constant for heat bath coupling, and a pressure relaxation time of 1 ps. The coordinates of the NPT-MD production runs, which were 10 ns long, were saved every 500 steps (1 ps intervals) for subsequent analysis.

Results and Discussion

Geometry optimization at the B3LYP/6-311+G(d,p) level led to the characterization of 28 and 23 different minimum energy structures for Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe, respectively. These minima are within relative energy (ΔE) intervals of 36.7 and 20.8 kcal/mol, respectively. Figure 3 represents the $\phi\psi$ backbone dihedral angles of these minima using a color scale (dark blue-to-white) to show the ΔE increase through intervals of 5 kcal/mol. As it can be seen, almost all regions of the Ramachandran map are visited because of the large number of minima characterized. However, the conformational space available to the compounds investigated is relatively restricted, especially that corresponding to the *trans*-c₅Arg derivative. Thus, only 8 out of the 28 minima found for Ac-*t*-L-c₅Arg-NHMe have ΔE values lower than 5 kcal/mol, and all 8 exhibit conformations in the α_L region (left-handed α -helix; $\phi, \psi \approx 60^\circ, 50^\circ$) of the Ramachandran map. Regarding *cis*-c₅Arg, 7 (out of 23) minimum energy conformations have $\Delta E < 5$ kcal/mol and correspond to three different backbone conformations, namely α_L , C₇^{eq} (equatorial C₇ or inverse γ -turn; $\phi, \psi \approx -60^\circ, 60^\circ$) and C₅ (fully extended; $\phi, \psi \approx \pm 180^\circ, \pm 180^\circ$). Accordingly, the relative stability of the minimum energy conformations characterized for these c₅Arg derivatives is strongly influenced by the *cis/trans* disposition of the charged substituent.

The next two sections present a detailed description of those minimum energy conformations characterized for the compounds under study that are more favored, not only in the gas phase but also in chloroform and water solutions. These minima are denoted using three labels. The first one refers to the backbone conformation type, defined by the $\phi\psi$ dihedral angles. The second label corresponds to the puckering of the cyclopentane ring, *i.e.* endo/exo-envelope (E) or twist (T) conformations (Scheme 1). Finally, the third label indicates the conformation of the guanidinium side chain, that is, the *trans* (t), *gauche*⁺ (g⁺) or *gauche*⁻ (g⁻) arrangement of the dihedral angles ξ_1 and ξ_2 .

Ac-*t*-L-c₅Arg-NHMe

Table 1 lists the backbone and side-chain dihedral angles of the 13 minimum energy conformations calculated for the *trans*-c₅Arg derivative with $\Delta E < 7$ kcal/mol. The global minimum corresponds to an $\alpha_L/\gamma^-E/g^-t$ conformation (Figure 4a), in which the backbone adopts an α -helical structure and the cyclopentane ring accommodates a C'^γ-exo envelope (γ^-E) arrangement. This geometry, combined with the *gauche*⁻/*trans* disposition of ξ_1/ξ_2 , allows the formation of a strong hydrogen bond between the guanidinium NH and the carbonyl oxygen of the acetyl blocking group [$d(H\cdots O) = 1.706 \text{ \AA}$, $\angle N-H\cdots O = 170.0^\circ$]. Modification of the envelope arrangement of the cyclopentane moiety from C'^γ-exo (γ^-E) to C'^γ-endo (γ^+E) gives rise to a new minimum ($\alpha_L/\gamma^+E/g^-t$, Figure 4b), that maintains all other conformational features present in the global minimum, including the side-chain $\cdots$ backbone interaction. This γ^-E -to- γ^+E transition is associated with an energy penalty of 1.6 kcal/mol.

The conformation adopted by both the peptide backbone and the cyclopentane ring in the lowest energy conformer is maintained in the third ($\alpha_L/\gamma^-E/tg^+$, Figure 4c), fourth ($\alpha_L/\gamma^-E/g^-g^-$, Figure 4d), sixth ($\alpha_L/\gamma^-E/g^+t$, Figure 4f) and eighth ($\alpha_L/\gamma^-E/g^-g^-$, Figure 4h) minima, which present ΔE values ranging from 2.5 to 4.4 kcal/mol. Thus, minima # 1, 3, 4, 6 and 8 differ mainly in the arrangement of the guanidinium substituent. The diverse orientations exhibited by this group translate into different hydrogen-bonding schemes involving the donor sites in the side chain (NH/NH₂) and the backbone carbonyl groups. Notably enough, two of such side-chain $\cdots$ backbone interactions exist simultaneously in minimum # 4 (Figure 4d), although none of them present an optimal geometry. Moreover, to allow their formation, the ψ angle deviates by around 25° from the value characterizing the rest of α_L/γ^-E conformers (Table 1).

On the other hand, changing the cyclopentane envelope arrangement in minimum # 3 from C γ' -exo to C γ' -endo results in a new minimum (# 7, $\alpha_L/\gamma'E/tg^+$, Figure 4g), which is 1.3 kcal/mol higher in energy. This destabilization is similar to that produced on going from the first to the second minima, which implies the same conformational change.

Finally, two other minimum energy conformations with an α_L backbone structure and $\Delta E < 7$ kcal/mol were located for Ac-*t*-L-c₅Arg-NHMe, namely conformers # 5 ($\alpha_L/^aE/g^+t$, Figure 4e) and # 11 ($\alpha_L/^aE/tg^+$, Figure 4k). They present ΔE values of 3.0 and 6.2 kcal/mol, respectively, and are the only minima in Table 1 exhibiting an α_L backbone conformation in which the flap of the cyclopentane envelope is occupied by the α instead of the γ' carbon. The fact that no minima with an atom other than C γ' at the envelope flap is located below $\Delta E = 3$ kcal/mol is a significant difference with respect to the unsubstituted derivative Ac-Ac₅c-NHMe, for which the global minimum was found to exhibit an aE cyclopentane arrangement.^{4a}

The most stable conformer with a backbone disposition other than α_L is # 9, which is unfavored by 5.2 kcal/mol with respect to the global minimum. In this structure (C $_7^{eq}/^aE/tg^+$, Figure 4i), the terminal backbone CO and NH sites form an intramolecular hydrogen bond [$d(H\cdots O) = 1.948$ Å, $\angle N-H\cdots O = 141.6^\circ$] defining a seven-membered cycle (C $_7$ or γ -turn conformation) and the cyclopentane ring adopts a C a -exo envelope arrangement. Furthermore, the side chain orientation allows the formation of an additional hydrogen bond involving the c₅Arg CO and the guanidinium NH₂ [$d(H\cdots O) = 1.671$ Å, $\angle N-H\cdots O = 175.3$]. The other minimum with a C $_7$ backbone structure (C $_7^{eq}/^aE/tg^-$, Figure 4m) exhibits similar backbone...backbone and side-chain...backbone interactions and differs from the former in the endo position occupied by C a within the cyclopentane envelope.

Two additional types of peptide backbone conformation, corresponding to extended (β -pleated sheet) or semi-extended (polyproline II) structures were detected among the minima characterized for Ac-*t*-L-c₅Arg-NHMe with $\Delta E < 7$ kcal/mol, namely minima # 10 ($\beta_L/^aE/g^-t$, Figure 4j) and # 12 (P $_{II}/\gamma'E/g^-t$, Figure 4l). They share a common disposition for the guanidinium side group (*gauche*-/*trans* arrangement of ξ_1/ξ_2), that, combined with the different backbone and cyclopentane conformations, leads to the formation of two and one side-chain...backbone interactions, respectively, for minima # 10 and 12.

Table 2 shows the conformational Gibbs free energies in the gas phase at 298K (ΔG_{gp}) for the minima listed in Table 1. It is worth noting that the addition of the ZPVE, thermal and entropic contributions to the ΔE values does not produce significant changes in the relative stability order outlined above. Thus, assuming a Boltzmann distribution, $\alpha_L/\gamma'E/g^-t$ is the only conformation with a significant population at room temperature in the gas phase, since the ΔG_{gp} values of all other minima are above 1.5 kcal/mol (Table 2). Furthermore, the backbone adopts an α_L conformation in the seven structures with lower ΔG_{gp} values, indicating that the preference for this helical fold is not altered by the addition of the statistical corrections. Not surprisingly, ΔG_{gp} values above 7 kcal/mol were obtained for all the minima with $\Delta E > 7$ kcal/mol and, therefore, the contribution of these structures to the conformational preferences of Ac-*t*-L-c₅Arg-NHMe are completely negligible.

The conformational free energies estimated in chloroform (ΔG_{CHL}^{conf}) and water (ΔG_{WAT}^{conf}) solutions at the same temperature are also included in Table 2. As it can be seen, $\alpha_L/\gamma'E/tg^+$ (Figure 4c) becomes the most favored conformation in both solvents, with $\alpha_L/\gamma'E/tg^+$ (Figure 4g) being destabilized by only 1.2 and 1.3 kcal/mol in chloroform and water, respectively. These results indicate that the solvent affects the arrangement of the side chain and, to some extent, the puckering of the cyclopentane ring but not the backbone, which in solution retains the preference for the α -helical conformation previously detected in the gas phase.

At this point, it is interesting to establish a comparison between the results obtained in this work for Ac-*t*-L-c₅Arg-NHMe and those recently reported for the analogous phenylalanine derivative, Ac-*t*-L-c₅Phe-NHMe.^{8a} Thus, for the *trans*-c₅Phe-containing compound, four different peptide backbone conformations were found to be energetically accessible in the gas phase. They correspond to C₇^{eq}, C₅, C₇^{ax} and α_R structures, the three latter being destabilized with respect to the former by 0.6, 1.0, and 1.5 kcal/mol, respectively. In comparison, only the α_L backbone conformation is accessible to Ac-*t*-L-c₅Arg-NHMe, with no other being located within ΔE < 5 kcal/mol (Table 1). The cyclopentane ring puckering propensities are also significantly different for the two compounds. Thus, ^aE, ^γE and ^αE arrangements were characterized in the accessible minima of the *trans*-c₅Phe derivative,^{8a} whereas for Ac-*t*-L-c₅Arg-NHMe only the ^γE disposition is detected. Regarding the behavior in solution, the environment was found to alter the conformational preferences of the *trans*-c₅Phe derivative from a quantitative point of view but not qualitatively, that is, both compounds retain the main conformational trends observed in the gas phase.

This comparison provides evidence for the different roles played by the guanidinium and phenyl side groups in directing the conformational preferences of Ac₅c and indicates that the presence of a charged guanidinium group in the neighborhood of the carbonyl terminus (*trans*-c₅Arg) imposes more severe conformational constraints than those induced when an aromatic group is incorporated in the same position (*trans*-c₅Phe). This distinct behavior should be attributed to the different types of interactions that each side group may establish with the backbone. Thus, the phenyl substituent may affect the conformational propensities of the rest of the molecule by steric reasons or through the establishment of weak attractive interactions of the N-H...π type²¹ with the NH groups in the peptide backbone. In comparison, the guanidinium side chain mainly interacts with the backbone through the formation of hydrogen bonds. The latter interactions have a more marked directional character, involve the CO instead of the NH backbone groups and are associated with a much higher energy. As a consequence, the guanidinium side chain specifically oriented by the cyclopentane ring towards the carbonyl terminus has a greater impact on the conformational properties of the peptide backbone than a phenyl substituent, and induces conformations different to those encountered for peptides incorporating the unsubstituted Ac₅c^{4a} or the phenylalanine counterpart, *trans*-c₅Phe.^{8a}

Ac-C-L-c₅Arg-NHMe

The relevant structural parameters of the minimum energy conformations with ΔE < 7 kcal/mol characterized for Ac-*c*-L-c₅Arg-NHMe are listed in Table 3. As it can be seen, only 9 minima satisfy this energetic criterion. It should be noted that, at variance with the compound described in the previous section, in this c₅Arg derivative the charged guanidinium group exhibits a *cis* relative orientation with respect to the amino substituent (Figure 2). This should reflect in different interactions between the side chain and the rest of the molecule (both the cyclopentane ring and the peptide backbone) and therefore lead to different conformational propensities.

The lowest energy minimum characterized for Ac-*c*-L-c₅Arg-NHMe (α_L/^aE/g⁺g⁺, Figure 5a) corresponds to an α_L backbone conformation with the cyclopentane ring arranged as a C^α-exo envelope and the two side-chain dihedral angles in *gauche*⁺. This spatial organization orientates both backbone carbonyl oxygens (those in the acetyl group and the c₅Arg residue) towards the guanidinium side chain, thus allowing the existence of two side-chain...backbone hydrogen bonds. The second (α_L/^aE/g⁺t, Figure 5b), third (α_L/^aE/tg⁻, Figure 5c) and fourth (α_L/^aE/g⁺g⁺, Figure 5d) minima only differ from the global one in the orientation of the guanidinium side group. These conformational transitions bring about significant changes in the hydrogen bonding scheme and an energy destabilization ranging from 0.5 to 1.5 kcal/mol.

The next minimum ($C_7^{eq}/\alpha E/tg^-$, Figure 5e) adopts a different backbone conformation. Specifically, the backbone acetyl CO and methylamide NH groups form a seven-membered hydrogen-bonded ring typical of the C_7 or γ -turn conformation. Additionally, this structure is stabilized by a strong side-chain...backbone interaction involving one guanidinium NH_2 and the c_5Arg CO group. The arrangement of the cyclopentane ring is identical to that observed for the four preceding minima. Conformer # 6 ($C_7^{eq}/\alpha E/g^+t$, Figure 5f) differs from # 5 in the orientation of the side group only, and this is associated with a change in the side-chain...backbone hydrogen-bonding pattern and an energy cost of 0.8 kcal/mol.

The next two structures, minima # 7 ($C_5/\eta' E/g^+t$, Figure 5g) and # 8 ($C_5/\eta' E/tg^+$, Figure 5h), correspond to a C_5 peptide backbone conformation, characterized by the presence of a hydrogen bond linking the c_5Arg NH and CO sites and closing a five-membered cycle. In the case of minimum # 7, the geometry of this pseudocycle is severely distorted—as evidenced by the small ψ angle—to allow the involvement of the same CO group in a strong hydrogen bond with the guanidinium NH site. The different orientation of the guanidinium side chain in minimum # 8 leads to an interaction with the acetyl CO group (instead of the c_5Arg CO), and the C_5 conformation accommodated by the peptide backbone is completely regular. It is also noteworthy that # 7 is the most stable minimum of the *cis*- c_5Arg derivative in which the flap of the cyclopentane envelope is not occupied by the α carbon. This means a significant difference with reference to the behavior described above for the *trans*- c_5Arg derivative.

Finally, the last conformer in Table 3 ($P_{II}/\alpha E/g^-g^+$, Figure 5i) is disfavored by 6.9 kcal/mol with respect to the global minimum and corresponds to a polyproline II conformation stabilized by a single side-chain...backbone interaction.

Inspection of Table 4 indicates that the lowest ΔG_{gp} value corresponds to the $\alpha_L/\alpha E/g^+t$ conformation (Figure 5b), while the $\alpha_L/\alpha E/g^+g^+$ minimum (Figure 5d) is destabilized by 1.8 kcal/mol. Accordingly, if a Boltzmann distribution is assumed, only the α_L backbone conformation and the C^α -exo envelope arrangement of the cyclopentane ring are populated in the gas phase at 298 K. For all the minima with $\Delta E > 7.0$ kcal/mol, ΔG_{gp} values above 5.1 kcal/mol were obtained and, therefore, the contribution of these structures to describe the conformational preferences of *cis*- c_5Arg can be considered as negligible.

The values of ΔG_{CHL}^{conf} and ΔG_{WAT}^{conf} are also listed in Table 4. As it can be seen, the only conformations with $\Delta G_{CHL}^{conf} < 1.5$ kcal/mol are $\alpha_L/\alpha E/tg^-$ (Figure 5c), which is the global minimum in chloroform solution, and $C_7^{eq}/\alpha E/tg^-$ (Figure 5e), that is destabilized by 1.0 kcal/mol. Accordingly, both the α_L and C_7^{eq} backbone conformations are expected to exhibit significant populations in this organic solvent, while the disposition of the cyclopentane ring and the guanidinium side chain seems to be restricted to the C^α -exo envelope and tg^- arrangements, respectively. On the other hand, the lowest energy minimum in aqueous solution is $\alpha_L/\alpha E/tg^-$ (Figure 5c), all the other structures being destabilized by more than 3.3 kcal/mol. It is worth noting that the $\alpha_L/\alpha E/g^+t$ conformation (Figure 5b), which presented the lowest ΔG_{gp} value, is disfavored by 3.1 and 4.9 kcal/mol in chloroform and water, respectively.

Again, significant differences are detected when the results obtained in this work for Ac-*c*-L- c_5Arg -NHMe are compared to those previously described for Ac-*c*-L- c_5Phe -NHMe.^{8a} Notably, the conformational space available to the latter compound was found to be more restricted than that of the *trans* derivative as a consequence of the high proximity between the amino terminus and the bulky, rigidly held aromatic substituent. Thus, only equatorial C_7 conformers were found to be accessible at room temperature for Ac-*c*-L- c_5Phe -NHMe. Indeed, for this compound, minima with an α_L backbone arrangement were destabilized by more than

5 kcal/mol, whereas this is the only backbone structure energetically accessible to *cis*-c₅Arg (Table 3). Also the cyclopentane arrangement was found to be substantially different. Thus, the β E disposition, which places the β carbon bearing the bulky phenyl ring out of the plane defined by the other cyclopentane atoms, proved the most favorable one for the *cis*-c₅Phe derivative,^{8a} whereas *cis*-c₅Arg largely prefers the α E arrangement. In chloroform and aqueous solution, C₇^{eq}/ β E remained the only structure energetically accessible to Ac-*c*-L-c₅Phe-NHMe. Accordingly, the conformational preferences of *cis*-c₅Phe and *cis*-c₅Arg are substantially different since they depend, to a large extent, on the need to relieve steric hindrance in the former case and on the ability of the side chain to form hydrogen bonds with the backbone in the latter.

Classical Molecular Dynamics simulations in aqueous solution

In the absence of experimental data, classical MD simulations with explicit solvent molecules are valuable for describing the favored low-energy conformations of peptides. In order to explore the conformational energy surfaces of Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe in aqueous solution using this methodology, a specific force-field parametrization to represent the stretching, bending, torsional, van der Waals and electrostatic interactions of these constrained peptides was required. In a previous study we showed that no special electronic effect is present in Ac₅c^{4a} and, therefore, the stretching, bending, torsional and van der Waals parameters for Ac₅c and its derivatives can be directly transferred from the Amber force-field.²² Accordingly, electrostatic charges have been the only force-field parameters specifically developed for *trans*- and *cis*-c₅Arg.

Atomic charges for the five minimum energy conformations listed in Table 1 and 3 were calculated by fitting the HF/6-31G(d) quantum mechanical and the Coulombic molecular electrostatic potentials (MEPs) to a large set of points placed outside the nuclear region. It should be noted that the electrostatic parameters derived at this level of theory are fully compatible with the current Amber force-field.²² Electrostatic potential (ESP) fitting atomic centered charges for *trans*- and *cis*-c₅Arg were derived by weighting the charges calculated for the corresponding minimum energy conformations according to Boltzmann populations.²³ The weights were given by the standard Boltzmann formula using the ΔG_{gp} values given in Tables 2 and 4. As the charges obtained for *trans*- and *cis*-c₅Arg were similar, *i.e.* the absolute value of the largest was lower than 0.08 e.u., we decided to simplify the force-field by providing a unique set of electrostatic parameters for the two amino acids (Figure 6).

MD simulations of Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe were performed at 350 K. The lowest energy conformation was used as starting point of a trajectory that was 10 ns long for each compound. Figure 7 represents the accumulated Ramachandran plot for the *trans*- and *cis*-c₅Arg dipeptides. In both cases the most populated conformation in aqueous solution corresponds to the α_L , which is visited much more frequently than the C₇^{eq} conformation during the trajectory. This fact is in excellent agreement with the results displayed in Table 2 and 4, which indicate that the α_L conformation is the lowest energy minimum. These evidences clearly confirm that the conformational space of both *trans*- and *cis*-c₅Arg is severely restricted by the constraints imposed not only by the cyclopentane ring but also by the charged guanidinium group, which establish hydrogen-bond interactions with the peptide backbone.

Influence of the guanidinium side group in the conformational properties

In order to evaluate quantitatively the consequences arising from the incorporation of the guanidinium side group in Ac₅c to generate *cis*- and *trans*-c₅Arg, the isodesmic reaction displayed in Scheme 1 has been considered. For different backbone conformations and cyclopentane ring arrangements, the energy (E^g) and free energy (G^g) contribution associated with the side group in Scheme 1 were estimated according to equations (1) and (2), respectively.

$$E^{\text{sg}} = E^{\text{Ac-L-c}_5\text{Arg-NHMe}} + E^{\text{CH}_4} - (E^{\text{Ac-Ac}_5\text{c-NHMe}} + E^{\text{CH}_3\text{-R}}) \quad (1)$$

$$G^{\text{sg}} = G^{\text{Ac-L-c}_5\text{Arg-NHMe}} + G^{\text{CH}_4} - (G^{\text{Ac-Ac}_5\text{c-NHMe}} + G^{\text{CH}_3\text{-R}}) \quad (2)$$

In these equations, E^{sg} and G^{sg} provide an estimation of the energy and free energy contribution, respectively, associated to the incorporation of the guanidinium side group for a given backbone conformation and cyclopentane ring puckering of Ac₅c. Table 5 shows the values calculated considering selected minimum energy conformations of both Ac-*t*-L-c₅Arg-NHMe (Table 1) and Ac-*c*-L-c₅Arg-NHMe (Table 3), namely the most stable ones among those for which Ac-Ac₅c-NHMe was found ^{4a} to exhibit a minimum with similar backbone conformation and cyclopentane puckering. As no α_{L} minimum with an ^aE cyclopentane arrangement was characterized for the *cis*-c₅Arg derivative, the $\alpha_{\text{L}}/\alpha\text{E/g}^+\text{g}^+$ conformation (the global minimum in Table 3) was considered in this case. On the other hand, it should be noted that the minimum energy conformations previously obtained for Ac-Ac₅c-NHMe through B3LYP/6-311G(d,p) calculations ^{4a} have been re-optimized at the B3LYP/6-311+G(d,p) level.

The negative values obtained for both E^{sg} and G^{sg} (Table 5) reveal significant favorable interactions for all the conformations of Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe considered. Specifically, the attractive interactions between the charged side group and the polar backbone amide groups produce a significant stabilization for C_{eq} and backbone conformations. The strength of this effect is fully the α_{L} , C₇^{eq} and C₅ consistent with the relative energies and free energies obtained for such conformations, the most and least attractive interaction being obtained for the α_{L} and C₅ structures, respectively. Overall, these results indicate that the remarkable preference of c₅Arg towards the α_{L} helical conformation is due to the formation of strong side-chain...backbone interactions, which are more attractive than those established for other backbone conformations. As expected, G^{sg} is higher than E^{sg} in all cases, which should be attributed to the unfavorable entropic contribution associated with the disappearance of the strong side chain...backbone interactions.

Conclusions

The conformational preferences of Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe have been explored using quantum mechanical calculations at the B3LYP/6-311+G(d,p) level. Results indicate that the *cis* and, particularly, the *trans* stereoisomers of c₅Arg prefer an α -helical conformation. Thus, all the minima found for Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe with $\Delta E \leq 4.4$ and 1.5 kcal/mol, respectively, exhibit this peptide backbone structure. Furthermore, the preference for the α -helical conformation is retained in solution. Also the cyclopentane ring puckering is significantly affected by the presence and orientation of the guanidinium side chain, and thus, *cis*- and *trans*-c₅Arg show a marked preference for the C γ' -exo and C α -exo envelope arrangements, respectively, in all environmental conditions considered.

The structural preferences exhibited by the c₅Arg derivatives are in high contrast with those previously observed for the analogous phenylalanine derivatives, Ac-*t*-L-c₅Phe-NHMe and Ac-*c*-L-c₅Phe-NHMe, which have been shown to prefer the C₇^{eq} arrangement. The unique conformational properties observed for c₅Arg should be attributed to the ability of the side-chain guanidinium group to establish hydrogen-bond interactions with the peptide backbone, which are particularly attractive when the backbone adopts a helical conformation. The present work provides evidence for the ability of the side chain to influence the peptide backbone

conformation and, specifically, illustrates how the latter may be affected by the side-chain nature and orientation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Gratitude is expressed to the Centre de Supercomputació de Catalunya (CESCA). Financial support from the Ministerio de Educación y Ciencia - FEDER (project CTQ2007-62245) and Gobierno de Aragón (research group E40) is gratefully acknowledged. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number N01-CO-12400. The content of this publication does not necessarily reflect the view of the policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government. This research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

References

1. (a) Toniolo C, Formaggio F, Kaptein B, Broxterman QB. *Synlett* 2006;1295. (b) Venkatraman J, Shankaramma SC, Balaram P. *Chem Rev* 2001;101:3131. [PubMed: 11710065] (c) Toniolo C, Crisma M, Formaggio F, Peggion C. *Biopolymers (Pept Sci)* 2001;60:396. (d) Benedetti E. *Biopolymers (Pept Sci)* 1996;40:3. (e) Toniolo C, Benedetti E. *Macromolecules* 1991;24:4004.
2. (a) Ballano G, Zanuy D, Jiménez AI, Cativiela C, Nussinov R, Alemán C. *J Phys Chem B* 2008;112:13101. [PubMed: 18811190] (b) Gómez-Catalán J, Alemán C, Pérez JJ. *Theor Chem Acc* 2000;103:380. (c) Alemán C. *J Phys Chem B* 1997;101:5046. (d) Valle G, Crisma M, Toniolo C, Holt EM, Tamura M, Bland J, Stammer CH. *Int J Pept Protein Res* 1989;34:56. [PubMed: 2793309] (e) Benedetti E, Di Blasio B, Pavone V, Pedone C, Santini A, Crisma M, Valle G, Toniolo C. *Biopolymers* 1989;28:175. (f) Crisma M, Bonora GM, Toniolo C, Barone V, Benedetti E, Di Blasio B, Pavone V, Pedone C, Santini A, Fraternali F, Bavoso A, Lelj F. *Int J Biol Macromol* 1989;11:345. [PubMed: 2489103] (g) Benedetti E, Di Blasio B, Pavone V, Pedone C, Santini A, Barone V, Fraternali F, Lelj F, Bavoso A, Crisma M, Toniolo C. *Int J Biol Macromol* 1989;11:353. [PubMed: 2489104] (h) Barone V, Fraternali F, Cristinziano PL, Lelj F, Rosa A. *Biopolymers* 1988;27:1673.
3. (a) Casanovas J, Zanuy D, Nussinov R, Alemán C. *Chem Phys Lett* 2006;429:558. (b) Rao SN, Chan MF, Balaji VN. *Bull Chem Soc Jpn* 1997;70:293. (c) Gatos M, Formaggio F, Crisma M, Toniolo C, Bonora GM, Benedetti E, Di Blasio B, Iacovino R, Santini A, Saviano M, Kamphuis J. *J Pept Sci* 1997;3:110. [PubMed: 9230476] (d) Balaji VN, Ramnarayan K, Chan MF, Rao SN. *Peptide Res* 1995;8:178. [PubMed: 7670233]
4. (a) Alemán C, Zanuy D, Casanovas J, Cativiela C, Nussinov R. *J Phys Chem B* 2006;110:21264. [PubMed: 17048955] (b) Aschi M, Lucente G, Mazza F, Mollica A, Morera E, Nalli M, Paglialunga Paradisi M. *Org Biomol Chem* 2003;1:1980. [PubMed: 12945783] (c) Valle G, Crisma M, Toniolo C. *Can J Chem* 1988;66:2575. (d) Crisma M, Bonora GM, Toniolo C, Benedetti E, Bavoso A, Di Blasio B, Pavone V, Pedone C. *Int J Biol Macromol* 1988;10:300. (e) Santini A, Barone V, Bavoso A, Benedetti E, Di Blasio B, Fraternali F, Lelj F, Pavone V, Pedone C, Crisma M, Bonora GM, Toniolo C. *Int J Biol Macromol* 1988;10:292.
5. (a) Harini VV, Aravinda S, Rai R, Shamala N, Balaram P. *Chem Eur J* 2005;11:3609. (b) Crisma M, Bonora GM, Toniolo C, Bavoso A, Benedetti E, Di Blasio B, Pavone V, Pedone C. *Macromolecules* 1988;21:2071. (c) Pavone V, Benedetti E, Barone V, Di Blasio B, Lelj F, Pedone C, Santini A, Crisma M, Bonora GM, Toniolo C. *Macromolecules* 1988;21:2064. (d) Paul PKC, Sukumar M, Bardi R, Piazzesi AM, Valle G, Toniolo C, Balaram P. *J Am Chem Soc* 1986;108:6363.
6. (a) Prasad S, Mathur A, Jaggi M, Singh AT, Mukherjee R. *J Pept Sci* 2007;13:544. [PubMed: 17617800] (b) Labudda-Dawidowska O, Wierzbna TH, Prahla A, Kowalczyk W, Gawinski L, Plackova M, Slaninová J, Lammek B. *J Med Chem* 2005;48:8055. [PubMed: 16335929] (c) Kowalczyk W, Prahla A, Dawidowska O, Derdowska I, Sobolewski D, Hartrodt B, Neubert K, Slaninová J, Lammek B. *J Pept Sci* 2005;11:584. [PubMed: 15747318] (d) Kowalczyk W, Prahla A, Derdowska I, Dawidowska O, Slaninová J, Lammek B. *J Med Chem* 2004;47:6020. [PubMed: 15537356] (e) García-Echeverría

- C, Gay B, Rahuel J, Furet P. *Bioorg Med Chem Lett* 1999;9:2915. [PubMed: 10571147] (f) Breveglieri A, Guerrini R, Salvadori S, Bianchi C, Bryant SD, Attila M, Lazarus LH. *J Med Chem* 1996;39:773. [PubMed: 8576920] (g) Sukumar M, Raj PA, Balaran P, Becker EL. *Biochem Biophys Res Commun* 1985;128:339. [PubMed: 3985973]
7. (a) Lasa M, Cativiela C. *Synlett* 2006:2517. (b) Lasa M, López P, Cativiela C. *Tetrahedron: Asymmetry* 2005;16:4022. (c) Cativiela C, Lasa P, López P. *Tetrahedron: Asymmetry* 2005;16:2613. (d) Cativiela C, López M, Lasa M. *Eur J Org Chem* 2004:3898. (e) Alías M, Cativiela C, Jiménez AI, López P, Oliveros L, Marraud M. *Chirality* 2001;13:48. [PubMed: 11135415] (f) Cativiela C, Díaz-de-Villegas MD, Jiménez AI, López P, Marraud M, Oliveros L. *Chirality* 1999;11:583. [PubMed: 10423286]
 8. (a) Casanovas J, Jiménez AI, Cativiela C, Nussinov R, Alemán C. *J Org Chem* 2008;73:644. [PubMed: 18081347] (b) Lasa M, Jiménez AI, Zurbano MM, Cativiela C. *Tetrahedron Lett* 2005;46:8377. (c) Alemán C, Jiménez AI, Cativiela C, Pérez JJ, Casanovas J. *J Phys Chem B* 2002;106:11849. (d) Gomez-Catalán J, Jiménez AI, Cativiela C, Perez JJ. *J Pept Res* 2001;57:435. [PubMed: 11437947] (e) Jiménez AI, Cativiela C, Gómez-Catalán J, Pérez JJ, Aubry A, París M, Marraud M. *J Am Chem Soc* 2000;122:5811. (f) Jiménez AI, Cativiela C, París M, Peregrina JM, Avenoza A, Aubry A, Marraud M. *Tetrahedron Lett* 1998;39:7841. (g) Jiménez AI, Cativiela C, Aubry A, Marraud M. *J Am Chem Soc* 1998;120:9452. (h) Jiménez AI, Vanderesse R, Marraud M, Aubry A, Cativiela C. *Tetrahedron Lett* 1997;38:7559.
 9. (a) Crisma M, Toniolo C, Royo S, Jiménez AI, Cativiela C. *Org Lett* 2006;8:6091. [PubMed: 17165937] (b) Crisma M, De Borggraeve WM, Peggion C, Formaggio F, Royo S, Jiménez AI, Cativiela C, Toniolo C. *Chem Eur J* 2006;12:251. (c) Jiménez AI, Ballano G, Cativiela C. *Angew Chem Int Ed* 2005;44:396. (d) Royo S, De Borggraeve WM, Peggion C, Formaggio F, Crisma M, Jiménez AI, Cativiela C, Toniolo C. *J Am Chem Soc* 2005;127:2036. [PubMed: 15713068]
 10. Gaussian 03, Revision B.02, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A.; Vreven, Jr., T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; C. Strain, M.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian, Inc., Pittsburgh PA, 2003.
 11. Becke AD. *J Chem Phys* 1993;98:1372.
 12. Lee C, Yang W, Parr RG. *Phys Rev B* 1993;37:785.
 13. McLean AD, Chandler GS. *J Chem Phys* 1980;72:5639.
 14. (a) Miertus S, Scrocco E, Tomasi J. *Chem Phys* 1981;55:117. (b) Miertus S, Tomasi J. *Chem Phys* 1982;65:239. (c) Tomasi J, Persico M. *Chem Phys* 1994;94:2027. (b) Tomasi J, Mennucci B, Cammi R. *Chem Rev* 2005;105:2999. [PubMed: 16092826]
 15. Hawkins GD, Cramer CJ, Truhlar DG. *J Chem Phys B* 1998;102:3257. (b) Jang YH, Goddard WA III, Noyes KT, Sowers LC, Hwang S, Chung DS. *J Phys Chem B* 2003;107:344. (c) Iribarren JI, Casanovas J, Zanuy D, Alemán C. *Chem Phys* 2004;302:77.
 16. Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, Schulten K. *J Comput Phys* 1999;151:283.
 17. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. *J Chem Phys* 1982;79:926.
 18. Darden T, York D, Pedersen L. *J Chem Phys* 1993;98:10089.
 19. Ryckaert JP, Ciccotti G, Berendsen HJC. *Comput Phys* 1990;94:1683.
 20. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. *J Chem Phys* 1984;81:3684.
 21. (a) Steiner T, Koellner G. *J Mol Biol* 2001;305:535. [PubMed: 11152611] (b) Worth GA, Wade RC. *J Phys Chem* 1995;99:17473. (c) Mitchell JBO, Nandi CL, McDonald IK, Thornton JM. *J Mol Biol* 1994;239:315. [PubMed: 8196060] (d) Mitchell JBO, Nandi CL, Ali S, McDonald IK, Thornton JM. *Nature* 1993;366:413.

22. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. *J Am Chem Soc* 1995;117:5179.
23. Alemán C, Casanovas. *J Chem Soc Perkin Trans 2* 1994:563.

Figure 1.

Structure of 1-aminocycloalkane-1-carboxylic acids (Ac_nC , n : cycle size) and a proteinogenic amino acid (represented, in general, as Xaa). Combination of the cyclic structure of Ac_nC with the side-chain functionality in Xaa gives rise to c_nXaa residues.

Figure 2. Structure of the compounds investigated, containing the *trans* (*t*) and *cis* (*c*) cyclopentane analogues of L-arginine. The backbone and side-chain dihedral angles are indicated.

Figure 3.

Distribution on the Ramachandran map of the minimum energy conformations characterized at the B3LYP/6-311+G(d,p) level for the two $c_5\text{Arg}$ derivatives under study. The color and size of the symbols used to represent the backbone conformations depend on the relative energy (ΔE) values. Specifically, large and dark blue circles correspond to the more stable minima, while small and empty circles are the least stable ones, *i.e.* both the intensity of the color and the size of the circles decrease when the relative energy increases.

Figure 4.

Lower minimum energy conformations of Ac-*t*-L-c₅Arg-NHMe obtained from B3LYP/6-311 +G(d,p) calculations. The 13 structures depicted correspond to the minima listed in Table 1, *i.e.* minimum energy conformations with $\Delta E < 7$ kcal/mol.

Figure 5.

Lower minimum energy conformations of Ac-c-L-c5Arg-NHMe obtained from B3LYP/6-311 +G(d,p) calculations. The 9 structures depicted correspond to the minima listed in Table 3, *i.e.* minimum energy conformations with $\Delta E < 7$ kcal/mol.

Figure 6.
Electrostatic parameters determined for c₅Arg residues.

Figure 7. Accumulated Ramachandran plot for Ac-*t*-L-c5Arg-NHMe and Ac-*c*-L-c5Arg-NHMe derived from a MD trajectory 10 ns long in aqueous solution.

Scheme 1.

Scheme 2.

Dihedral angles^a and relative energies in the gas phase (ΔE) for the minimum energy conformations with $\Delta E < 7.0$ kcal/mol characterized for Ac-t-L-c5Arg-NHMe at the B3LYP/6-311+G(d,p) level.

Table 1

#	Conformer	Backbone dihedral angles			Cyclopentane dihedral angles					Side group	
		ω_0	ϕ	ψ	ω	χ^1	χ^2	χ^3	χ^4	χ^5	ξ_1, ξ_2 ΔE^b
1	$\alpha_L/\text{E/g}^- \text{t}$	174.8	71.9	19.8	174.5	-0.1	25.3	-40.9	41.2	-25.2	-63.3, 166.9
2	$\alpha_L/\text{E/g}^- \text{t}$	174.6	71.2	19.6	173.6	-3.9	-21.2	38.6	-41.3	27.8	-59.3, 164.3
3	$\alpha_L/\text{E/tg}^+$	177.5	79.0	14.3	177.2	-7.4	31.2	-42.8	38.3	-18.9	-162.8, 96.8
4	$\alpha_L/\text{E/g}^- \text{g}^-$	176.2	59.1	45.5	177.9	4.6	21.0	-38.8	42.0	-28.6	-62.7, -94.1
5	$\alpha_L/\text{E/g}^+ \text{t}$	172.2	56.9	42.2	178.8	-39.0	22.3	4.1	-29.2	41.7	68.4, 174.4
6	$\alpha_L/\text{E/g}^+ \text{t}$	173.0	74.0	21.1	176.6	-8.7	32.0	-42.9	37.8	-17.7	75.1, 148.8
7	$\alpha_L/\text{E/tg}^+$	177.8	79.0	16.3	176.5	-11.1	-13.3	33.0	-40.4	31.7	-161.8, 98.1
8	$\alpha_L/\text{E/g}^- \text{g}^-$	174.7	80.5	17.5	174.3	10.4	15.4	-35.5	42.4	-32.6	-50.3, -87.0
9	$C_7^{\text{eq}}/\alpha/\text{E/tg}^+$	-177.8	-73.8	74.8	-175.5	45.0	-34.8	11.1	17.0	-38.2	-155.2, 85.4
10	$\beta_L/\text{E/g}^- \text{t}$	164.7	150.9	119.9	179.0	-44.9	36.8	-13.5	15.2	37.0	-68.5, 125.5
11	$\alpha_L/\text{E/tg}^+$	174.9	60.0	48.4	-179.4	45.3	-38.2	16.6	11.9	-35.4	-143.9, 82.9
12	$P_{\text{II}}/\text{E/g}^- \text{t}$	-170.5	71.0	155.3	-176.0	-5.1	17.8	34.0	-37.7	26.4	-65.0, 159.9
13	$C_7^{\text{eq}}/\alpha/\text{E/tg}^-$	-170.5	-75.2	57.3	179.2	-41.0	24.8	15.6	-27.4	41.9	147.0, -98.3

^aIn degrees; see Figure 2 for definition.

^bIn kcal/mol.

^c $E = -856.744293$ a.u.

Table 2

Relative conformational Gibbs free energies^a at 298K for selected^b minimum energy conformations of Ac-*t*-L-c₅Arg-NHMe in the gas phase (ΔG_{gp}), chloroform ($\Delta G_{\text{CHL}}^{\text{conf}}$) and aqueous solution ($\Delta G_{\text{WAT}}^{\text{conf}}$) characterized at the B3LYP/6-311+G(d,p) level.

#	Conformer	ΔG_{gp}	$\Delta G_{\text{CHL}}^{\text{conf}}$	$\Delta G_{\text{WAT}}^{\text{conf}}$
1	$\alpha_{\text{L}}/\gamma\text{E/g}^-\text{t}$	0.0 ^c	2.0	3.2
2	$\alpha_{\text{L}}'/\gamma\text{E/g}^-\text{t}$	1.6	3.1	4.8
3	$\alpha_{\text{L}}/\gamma\text{E/tg}^+\text{t}$	2.8	0.0	0.0
4	$\alpha_{\text{L}}/\gamma\text{E/g}^-\text{g}^-\text{t}$	4.1	4.0	5.2
5	$\alpha_{\text{L}}'/\alpha\text{E/g}^+\text{t}$	2.4	3.6	4.1
6	$\alpha_{\text{L}}/\gamma\text{E/g}^+\text{t}$	3.8	3.9	4.7
7	$\alpha_{\text{L}}'/\gamma\text{E/tg}^+\text{t}$	4.2	1.2	1.3
8	$\alpha_{\text{L}}/\gamma\text{E/g}^-\text{g}^-\text{t}$	6.2	5.9	7.4
9	$\text{C}_7^{\text{eq}}/\alpha\text{E/tg}^+\text{t}$	6.4	1.5	1.3
10	$\beta_{\text{L}}/\alpha\text{E/g}^-\text{t}$	6.9	6.7	8.4
11	$\alpha_{\text{L}}/\alpha\text{E/tg}^+\text{t}$	6.4	3.6	3.1
12	$\text{P}_{\text{II}}'/\gamma\text{E/g}^-\text{t}$	5.7	7.7	8.6
13	$\text{C}_7^{\text{eq}}/\alpha\text{E/tg}^-\text{t}$	8.2	3.8	4.2

^a In kcal/mol.

^b Minimum energy conformations with $\Delta E < 7.0$ kcal/mol (see Table 1).

^c $G = -856.436015$ a.u

Table 3

Dihedral angles^a and relative energies in the gas phase (ΔE) for the minimum energy conformations with $\Delta E < 7.0$ kcal/mol characterized for Ac-c-L-c5Arg-NHMe at the B3LYP/6-311+G(d,p) level.

#	Conformer	Backbone dihedral angles			Cyclopentane dihedral angles					Side group		
		ω_0	ϕ	ψ	ω	χ^1	χ^2	χ^3	χ^4	χ^5	ξ_1, ξ_2	ΔE^b
1	$\alpha_{L/a}E/g^+g^+$	-178.5	48.0	48.6	180.0	40.4	-26.7	2.0	23.8	-39.6	63.0, 84.6	0.0 ^c
2	$\alpha_{L/a}E/g^+t$	-178.5	48.6	51.6	179.4	43.4	-32.1	7.7	19.9	-38.9	69.5, -163.2	0.5
3	$\alpha_{L/a}E/tg^-$	180.0	49.8	45.0	-178.7	44.6	-35.2	11.5	16.5	-37.3	151.6, -86.3	1.4
4	$\alpha_{L/a}E/g^+g^+$	-178.3	49.6	42.5	178.1	41.3	-28.6	4.0	22.2	-39.0	54.2, 84.6	1.5
5	$C_7^{eq}/aE/tg^-$	-172.0	-72.9	60.3	179.2	42.3	-29.9	5.4	21.0	-38.8	152.8, -84.2	2.3
6	$C_7^{eq}/aE/g^+t$	-173.0	-72.8	67.1	-179.6	42.6	-28.7	2.9	24.3	-41.1	70.3, 161.9	3.1
7	$C_5'/E/g^+t$	169.4	179.4	131.4	176.9	11.7	-33.6	42.7	-35.7	14.6	61.9, 166.4	4.9
8	$C_5'/E/tg^+$	169.5	-179.9	172.2	-177.3	13.9	-34.6	42.1	-33.5	11.9	-156.0, 99.8	6.1
9	$P_{H/a}E/g^+g^+$	-172.0	-57.8	129.1	-177.5	43.8	-29.4	3.3	24.5	-41.8	-66.6, 111.4	6.9

^aIn degrees; see Figure 2 for definition.

^bIn kcal/mol.

^c $E = -856.7433141$ a.u.

Table 4

Relative conformational Gibbs free energies^a at 298K for selected^b minimum energy conformations of Ac-*c*-L-c₅Arg-NHMe in the gas phase (ΔG_{gp}), chloroform ($\Delta G_{\text{CHL}}^{\text{conf}}$) and aqueous solution ($\Delta G_{\text{WAT}}^{\text{conf}}$) characterized at the B3LYP/6-311+G(d,p) level.

#	Conformer	ΔG_{gp}	$\Delta G_{\text{CHL}}^{\text{conf}}$	$\Delta G_{\text{WAT}}^{\text{conf}}$
1	$\alpha_{\text{L}}/\alpha\text{E/g}^+\text{g}^+$	2.0	2.4	4.6
2	$\alpha_{\text{L}}/\alpha\text{E/g}^+\text{t}$	0.0 ^c	3.1	4.9
3	$\alpha_{\text{L}}/\alpha\text{E/tg}^-$	2.1	0.0	0.0
4	$\alpha_{\text{L}}/\alpha\text{E/g}^+\text{g}^+$	1.8	3.4	5.4
5	$\text{C}_7^{\text{eq}}/\alpha\text{E/tg}^-$	3.4	1.0	3.3
6	$\text{C}_7^{\text{eq}}/\alpha\text{E/g}^+\text{t}$	2.9	4.5	7.5
7	$\text{C}_5/\gamma'\text{E/g}^+\text{t}$	8.2	5.6	6.9
8	$\text{C}_5/\gamma'\text{E/tg}^+$	5.5	3.9	6.1
9	$\text{P}_{\text{II}}/\alpha\text{E/g}^-\text{g}^+$	7.7	3.8	4.3

^a In kcal/mol.

^b Minimum energy conformations with $\Delta E < 7.0$ kcal/mol (see Table 3).

^c $G = -856.429193$ a.u.

Table 5

Energy (E^{sg}) and free energy (G^{sg}) contributions associated with the guanidinium side group for selected backbone conformations of Ac-*t*-L-c₅Arg-NHMe and Ac-*c*-L-c₅Arg-NHMe.

Compound	Conf. L-c ₅ Arg	Conf. Ac ₅ c ^a	E^{sg}	G^{sg}
Ac- <i>t</i> -L-c ₅ Arg-NHMe	$\alpha_L/\alpha E/g^+t$	$\alpha_L/\alpha E$	-17.1	-13.8
	$C_7^{\text{eq}}/\alpha E/tg^+$	$C_7^{\text{eq}}/\alpha E$	-12.5	-8.4
	$C_7^{\text{eq}}/\alpha E/tg^-$	$C_7^{\text{eq}}/\alpha E$	-11.1	-7.3
Ac- <i>c</i> -L-c ₅ Arg-NHMe	$\alpha_L/\alpha E/g^+g^+$	$\alpha_L/\alpha E$	-19.5	-13.7
	$C_7^{\text{eq}}/\alpha E/tg^-$	$C_7^{\text{eq}}/\alpha E$	-14.7	-10.9
	$C_5/\beta' E/g^+t$	$C_5/\beta' E$	-13.2	-9.8

^aFrom ref. 4a [minima re-optimized at the B3LYP/6-311+G(d,p) level]